Neurodegenerative diseases

  • Email
  • Help

This page brings together the Agency's latest information on diseases causing problems with the brain and nervous system, including Alzheimer's disease, Parkinson's disease and multiple sclerosis. It lists:

the ten newest and recently updated medicines authorised for the treatment of neurodegenerative diseases in the European Union (EU);

the most recent opinions on medicines for neurodegenerative diseases that are pending authorisation by the European Commission (EC);

the latest news and press releases related to neurodegenerative diseases;

the Agency's events on topics related to neurodegenerative diseases.

New and recently updated medicines

Opinions pending EC decision



  • 11/11/2016


    Spinal muscular atrophy workshop

    The European Medicines Agency (EMA), SMA Europe and TREAT NMD are co-organising a one-day workshop on spinal muscular atrophy (SMA) on 11th November this year. The workshop will bring together key stakeholders to discuss, help and advance the development of therapies for the treatment of SMA. Topics for discussion will include an overview of the disease, the pharmacology of the molecules under investigation, natural history data, clinical outcome measures and biomarkers. ... Read more

  • 24/11/2014 - 25/11/2014


    European Medicines Agency workshop on the clinical investigation of medicines for the treatment of Alzheimer's disease

    The Agency is organising this workshop following the public-consultation exercise on its concept paper on the need for revision of the guideline on medicinal products for the treatment of Alzheimer’s disease and other dementias. The aim of the workshop is to make sure that, while revising its guideline, the EMA can take the most up-to-date scientific developments in understanding and treating Alzheimer’s disease into consideration, as well as the positions of experts in the field. Registration is open until 01/07/2014. Places limited. ... Read more

  • 10/10/2014


    Regulatory workshop on clinical trials designs in neuromyelitis optica and spectrum disorders

    This workshop brings together patient representatives, healthcare professionals, regulators, pharma and ethicists to discuss trial designs in neuromyelitis optica (NMO), a rare neurological disorder. For evidence of efficacy, in NMO, the choice of comparator is problematic. The severity/lack of reversibility of NMO relapses, indicate that placebo comparators are difficult but evidence for current treatments appears lacking. Different regulatory agencies have different views on comparators in NMO attack prevention. For a rare debilitating disease with unmet medical need, a wider debate is being held to facilitate drug development for the benefit of NMO patients. See 'Documents’ tab for agenda and 'Multimedia' tab for video of the workshop. ... Read more

  • 17/10/2013


    Workshop on the clinical investigation of new medicines for the treatment of multiple sclerosis

    The main goal of the workshop is to make sure that in the revision of the multiple-sclerosis guideline, the European Medicines Agency can take the most up-to-date, state-of-the-art scientific developments in multiple sclerosis into consideration, as well as the positions of experts in the field on the main topics in the guideline. ... Read more

  • 08/11/2010


    Expert meeting in familial neurodegenerative disorders

    This meeting is creating a forum for discussion among stakeholders - academics, regulators, industry and patients - in order to provide a first approximation for the resolution of issues in familial neurodegenrative disorders. Autosomal dominant Alzheimer's disease (ADAD) and Huntington's disease (HD) are being used as models to illustrate the challenges in pre-symptomatic clinical design studies. The insights obtained from this discussion are expected to be applicable to other similar areas. ... Read more